PAVmed Inc. is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841), based in New York, NY. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $71 thousand and a loss of $4 million (its filed statements).
Product businessSurgical & Medical Instruments & ApparatusNew York, NYfilings since 20148 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3841, Surgical & Medical Instruments & Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 3.9 out of ten, 8 of 9 metrics filed and 1 estimated: past 2.9 out of ten, present 5.1 out of ten, future 3.2 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 1.9 out of ten. 15 warning events since 2017; the latest 2025-04-25. 19th percentile among 121 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 2.1 out of ten. -38.6% a year over 5 filed years; profitable in 2 of 5. 21st percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 5.9 out of ten. CrossAssetData estimate 5.9/10, confidence 20 of 100 (family median). 50th percentile among 86 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Financial health (present): 5.6 out of ten. ROE 1%: 1¢ of profit per shareholder dollar. Leverage 12%: owes 12¢ per asset dollar. 56th percentile among 120 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 3.5 out of ten. bottom 34% of 109 in its family; net margin 564.8%. 34th percentile among 109 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 6.4 out of ten. top 36% of 90 in its family for leadership; chief executive since 2016. 64th percentile among 90 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 3.5 out of ten. bottom 34% of 104 in its family for room to expand. 34th percentile among 104 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 1.1 out of ten. bottom 11% of 105 in its family for growth drivers. 11th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 6.0 out of ten. top 40% of 88 in its family for expectations against reality. 60th percentile among 88 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-27 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-13 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-14 (on EDGAR). Newest filing: Form 8-K, 2026-09-10. Filings on record since 2014. Read from EDGAR 2026-10-12.
Who runs it
Aklog, Lishan (Chairman and CEO); Glennon, Michael J (Vice Chairman); Mcgrath, Dennis M (President and CFO); O'Neil, Shaun (Chief Operating Officer); Lee, Victoria Tou-Ho (Chief Medical Officer); Gordon, Michael Adam (General Counsel); Agrawal, Sundeep (director); Baxter, Timothy E (director); Sparks, Ronald M (director); White, Debra (director). 10 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.